May 20, 2015Companion Medical announces completion of Series B financing
Eli Lilly and Company investment in Companion will support development of innovative insulin delivery for people living with diabetes.
SAN DIEGO, CA, May 20, 2015 -- Companion Medical, Inc., a San Diego-based medical device company developing advanced systems for delivery of insulin and other drugs, has announced the completion of a series B financing, led by an investment from Eli Lilly and Company (“Lilly”).
“We are very excited to have Lilly as the lead investor in our series B financing,” said Sean Saint, president and CEO of Companion Medical. “Lilly is a global leader in insulin, as well as other medicines and devices in the international diabetes space, and we look forward to their involvement in potentially bringing our device to market.”
Lilly’s investment, along with other investors, could potentially enable Companion to complete testing and 510(k) submission to the Food and Drug Administration of its Bluetooth-enabled insulin pen and associated smartphone app, which could address a significant unmet need in the diabetes space.
Divakar Ramakrishnan, vice president for Delivery and Device Research and Development at Lilly, noted, “Lilly is focused on delivering the broadest portfolio of diabetes treatments in the industry, including innovative delivery methods to advance the treatment of diabetes. Companion’s smart pen and app represent innovation that could one day fill a gap for millions of people with diabetes.”
Lilly will sit on the Board of Directors of Companion Medical.
April 28, 2014 Companion Medical announces investment by Diamyd Medical
Diamyd investment in Companion will lead to development of superior insulin treatment for people living with diabetes.
Companion Medical, Inc., a San Diego based medical device company developing advanced systems for delivery of insulin and other drugs, has announced an investment by Diamyd Medical AB. “We are very excited to have Diamyd make a substantial investment in our series A financing. Diamyd has deep experience and contacts in the international diabetes space and we look forward to their involvement,” said Sean Saint, President and CEO of Companion Medical. “Diamyd’s investment, along with our other investors, will enable Companion to complete development of our product, which we believe addresses a significant unmet need in the diabetes space.”
“We are very pleased to have had the opportunity to invest in Companion with its skilled and experienced team,” says Peter Zerhouni, President and CEO of Diamyd Medical. “This investment enables us to further expand our diabetes portfolio and enter the medical device market. Companion is developing products with a significant market potential. Diamyd will sit on the Board of Directors of Companion Medical as well as represent Companion in the Nordic countries.
For further information, please contact: Ken Sunshine, COO/CFO, Companion Medical, Inc. Email: email@example.com Phone: 301-379-4511
About Companion Medical: Companion Medical, Inc. is a San Diego based medical device company currently focused on the diabetes space. Companion is developing advanced tools and technologies for people living with diabetes who require insulin. While insulin pumps currently offer the best tools available, the vast majority of people with diabetes either cannot or will not use a pump. Companion is developing an innovative solution that combines the best attributes of current solutions with advanced data management technologies to address the large global market for insulin delivery systems.